Related Experiment Video

Updated: Jun 16, 2025

Spectrophotometric Screening for Potential Inhibitors of Cytosolic Glutathione S-Transferases
14:57

Spectrophotometric Screening for Potential Inhibitors of Cytosolic Glutathione S-Transferases

Published on: October 10, 2020

14.4K

Sulfamethoxazole-Trimethoprim Prophylaxis in Pediatric Oncology Patients With Glucose-6-Phosphate Dehydrogenase

Rachael M Stone1, Cyrine E Haidar1, Nancy M Kornegay1

  • 1From the Department of Pharmacy and Pharmaceutical Sciences.

The Pediatric Infectious Disease Journal
|August 20, 2024
PubMed

Insights

Sulfamethoxazole-trimethoprim (SMX-TMP) prophylaxis does not increase acute hemolytic anemia risk in pediatric oncology patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency. Studies show no significant difference in hemoglobin levels or transfusion needs between G6PD-deficient and non-deficient groups.

Area of Science:

  • Pediatric Hematology
  • Oncology
  • Infectious Disease Prophylaxis

Background:

  • Glucose-6-phosphate dehydrogenase (G6PD) deficiency is a common genetic disorder that can cause hemolytic anemia.
  • Pneumocystis jirovecii pneumonia (PJP) is a serious opportunistic infection in immunocompromised patients, particularly those undergoing cancer treatment.
  • Sulfamethoxazole-trimethoprim (SMX-TMP) is a standard prophylactic agent against PJP, but concerns exist regarding its potential to trigger hemolysis in G6PD-deficient individuals.

Purpose of the Study:

  • To investigate the association between SMX-TMP prophylaxis and acute hemolytic anemia in pediatric oncology patients with G6PD deficiency.
  • To compare the incidence of hemolysis and transfusion requirements in G6PD-deficient versus non-G6PD-deficient pediatric oncology patients receiving SMX-TMP.

Main Methods:

  • Retrospective chart review of pediatric oncology patients receiving SMX-TMP for PJP prophylaxis.
  • Comparison of changes in hemoglobin levels and need for blood transfusions between patients with and without G6PD deficiency.
  • Statistical analysis to determine the significance of observed differences.

Main Results:

  • No statistically significant difference in the change in hemoglobin levels was observed between the G6PD-deficient and non-G6PD-deficient groups after initiating SMX-TMP.
  • Transfusion requirements did not differ significantly between the two groups.
  • The study found no evidence of an increased frequency of acute hemolytic anemia in G6PD-deficient patients.

Conclusions:

  • SMX-TMP administered at prophylactic doses appears safe in pediatric oncology patients with G6PD deficiency.
  • The risk of acute hemolytic anemia is not significantly elevated in G6PD-deficient patients receiving SMX-TMP for PJP prophylaxis.
  • These findings support the continued use of SMX-TMP for PJP prophylaxis in this vulnerable population.

More Related Videos

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer06:21

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Published on: May 10, 2024

649
Renal Subcapsular Transplantation of 2'-Deoxyguanosine-Treated Murine Embryonic Thymus in Nude Mice07:39

Renal Subcapsular Transplantation of 2'-Deoxyguanosine-Treated Murine Embryonic Thymus in Nude Mice

Published on: July 19, 2019

10.9K

Related Concept Videos

Glucose Transporters01:27

Glucose Transporters

Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
22.6K
Inborn Errors of Metabolism01:20

Inborn Errors of Metabolism

Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
148
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K